Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Radiation in High-Risk H&N Cancer
NCT00904345Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2009
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Started Apr 2009; status: terminated.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00904345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00904345.